Peptides in Metabolic Disease

Overview

Peptide therapeutics have transformed the treatment landscape for metabolic diseases, most dramatically through the development of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies. The commercial and clinical success of semaglutide and tirzepatide has established peptides as the dominant therapeutic class for type 2 diabetes and obesity, generating intense research and investment into next-generation metabolic peptide drugs.

Beyond incretins, peptides play roles in virtually every aspect of metabolic regulation — from insulin and glucagon to amylin, leptin, and gut-brain signaling peptides. This broad biological relevance is fueling a diverse pipeline of peptide candidates for metabolic syndrome, non-alcoholic steatohepatitis (NASH), and related conditions.

The Incretin System

GLP-1 Biology

GLP-1 is a 30-amino-acid peptide hormone secreted by intestinal L-cells in response to nutrient ingestion. Its physiological effects include:

• Glucose-dependent insulin secretion — GLP-1 stimulates pancreatic beta cells to release insulin only when blood glucose is elevated, minimizing hypoglycemia risk
• Glucagon suppression — Reduces hepatic glucose output by inhibiting alpha-cell glucagon secretion
• Gastric emptying delay — Slows nutrient absorption, reducing postprandial glucose excursions
• Appetite suppression — Acts on hypothalamic and brainstem circuits to reduce food intake and promote satiety
• Beta-cell preservation — Promotes beta-cell proliferation and inhibits apoptosis in preclinical models

Native GLP-1 has a half-life of approximately 2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). For a deeper exploration of GLP-1 biology, see GLP-1 Research.

GIP Biology

Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino-acid incretin hormone secreted by intestinal K-cells. GIP stimulates insulin secretion, promotes fat storage in adipose tissue, and has emerging roles in bone metabolism and CNS function. Unlike GLP-1, the therapeutic potential of GIP was long underappreciated until the success of dual GIP/GLP-1 agonists demonstrated synergistic metabolic benefits.

Evolution of GLP-1 Receptor Agonists

First Generation

Early GLP-1 receptor agonists addressed the half-life problem through different strategies:

• Exenatide (Byetta) — Based on exendin-4, a peptide from Gila monster saliva that is naturally resistant to DPP-4 cleavage. Twice-daily injection.
• Liraglutide (Victoza/Saxenda) — A GLP-1 analog with a fatty acid chain that promotes albumin binding, extending the half-life to approximately 13 hours. Once-daily injection.

Second Generation

Further engineering produced longer-acting agents requiring less frequent dosing:

• Semaglutide (Ozempic/Wegovy/Rybelsus) — Incorporates a longer fatty acid linker and amino acid substitutions for enhanced albumin binding and DPP-4 resistance. Weekly subcutaneous injection or daily oral tablet.
• Dulaglutide (Trulicity) — GLP-1 analog fused to an Fc antibody fragment. Weekly injection.

The development of oral semaglutide (Rybelsus) using the SNAC absorption enhancer represented a landmark achievement in oral peptide delivery, though bioavailability remains low (approximately 1%) and higher oral doses are in development.

Weight Loss Outcomes

The metabolic peptide field was fundamentally transformed when semaglutide demonstrated mean weight loss of approximately 15% in the STEP clinical trials and tirzepatide showed even greater efficacy (up to 22.5% in the SURMOUNT-1 trial). These results repositioned obesity from a condition with limited pharmacotherapy options to one with highly effective medical treatments.

Dual and Triple Agonists

GIP/GLP-1 Dual Agonists

• Tirzepatide (Mounjaro/Zepbound) — The first approved dual GIP/GLP-1 receptor agonist. By activating both incretin receptors, tirzepatide achieves greater glycemic control and weight loss than GLP-1 agonists alone. The mechanism of GIP's contribution is an area of active research, with hypotheses including enhanced central appetite suppression and improved adipose tissue metabolism.

GLP-1/Glucagon Dual Agonists

Glucagon, traditionally viewed as a counter-regulatory hormone that raises blood glucose, also promotes energy expenditure, lipid oxidation, and hepatic fat reduction. Dual GLP-1/glucagon agonists aim to combine the appetite-suppressing and insulin-sensitizing effects of GLP-1 with the energy-expenditure-increasing effects of glucagon:

• Survodutide — A dual GLP-1/glucagon receptor agonist in clinical development for obesity and NASH
• Pemvidutide — Another dual agonist showing promise for weight loss and hepatic fat reduction

Triple Agonists

• Retatrutide — A triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase II data demonstrated unprecedented weight loss (up to 24.2% at 48 weeks), establishing retatrutide as potentially the most effective anti-obesity peptide in clinical development.

Amylin-Based Therapeutics

Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon, and reduces appetite through brainstem and area postrema signaling.

• Pramlintide (Symlin) — A synthetic amylin analog approved for type 1 and type 2 diabetes as an adjunct to insulin therapy
• Cagrilintide — A long-acting amylin analog in development. The combination of cagrilintide with semaglutide (CagriSema) is being evaluated for superior weight loss compared to either agent alone, targeting complementary appetite pathways.

Beyond Incretins: Emerging Targets

Peptide YY (PYY) Analogs

PYY, released by intestinal L-cells after meals, suppresses appetite through Y2 receptor activation in the hypothalamus. Long-acting PYY analogs are in early clinical development for obesity.

Oxyntomodulin Analogs

Oxyntomodulin, a gut peptide that naturally activates both GLP-1 and glucagon receptors, has inspired the development of engineered dual agonists with optimized receptor selectivity ratios.

FGF21 Analogs

While not a classical peptide, fibroblast growth factor 21 (FGF21) analogs are peptide-like biologics in development for NASH and metabolic syndrome, targeting hepatic fat metabolism and insulin sensitivity.

NASH and Liver Disease

The metabolic peptide pipeline increasingly targets non-alcoholic steatohepatitis, a condition with limited approved therapies:

• GLP-1 agonists (semaglutide) have demonstrated histological improvement in NASH
• Dual GLP-1/glucagon agonists show enhanced liver fat reduction through glucagon-mediated hepatic lipid oxidation
• FGF21 analogs and other peptide-like agents target hepatic stellate cells and fibrosis pathways

Manufacturing and Delivery Innovations

The commercial scale of metabolic peptide production is enormous, requiring:

• Efficient large-scale peptide synthesis and purification
• Advanced formulation for stability in auto-injector devices
• Continued development of oral delivery technologies to expand patient access
• Implantable and depot formulations for extended-release delivery

Challenges and Outlook

Key challenges in the metabolic peptide space include gastrointestinal side effects (nausea, vomiting) that limit dose titration, the need for chronic therapy (weight regain after discontinuation), supply constraints given enormous demand, and the high cost of peptide biologics.

The pipeline continues to evolve toward more efficacious multi-target agents, oral formulations, and combination therapies. The integration of AI-driven peptide design and novel chemical modifications is accelerating the identification of next-generation metabolic peptides with improved efficacy, tolerability, and convenience profiles.